Osteoboost Health Launches FDA-Cleared Prescription Wearable Device for Low Bone Density, Filling Critical Treatment Gap for 60M+ Americans
Osteoboost is a brand-new wearable that bridges the gap between next-generation consumer health technology and rigorously tested medical innovation. Designed for effortless, at-home use, this clinically proven device delivers targeted vibration therapy directly to the spine and hips: areas at high risk for osteoporotic fractures.
Osteoboost CEO Laura Yecie s said, 'Osteoboost empowers people to lead longer, stronger, and more active lives. While the belt is sophisticated medical technology rigorously tested and validated for efficacy, the treatment is easy - 30 minutes a day of vibration therapy that can be done while walking, or other activities.'
A gold-standard, double-blinded, placebo-controlled clinical trial at the University of Nebraska Medical Center demonstrated that Osteoboost slowed bone density and strength loss in postmenopausal women with osteopenia who used it at least 3 times per week:
85% reduction in the loss of bone density in the spine
83% reduction in the loss of bone strength in the spine
55% reduction in the loss of bone density in the hip
'It's been a long time since we've seen any innovation for bone health, and yet every day I see patients terrified of the risks they face just walking down the street,' said Dr. Yevgeniya Kushchaeva, Clinical Director of University of South Florida Health Adult Endocrinology, and Medical Director of Adult Osteoporosis Program. 'Osteoboost did this the right way. They spent years investing in the clinical trial and FDA approval processes - not easy even for larger pharmaceutical companies.'
Osteoboost also announced new strategic investments from AARP, Harvard Business School Angels, and She's Independent, plus a follow-on investment from Esplanade Healthtech Ventures.
Osteoboost is a medical technology company developing non-invasive, and science-backed solutions for people with low bone density. For more information, including Instructions for Use, visit https://osteoboost.com/.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 minutes ago
- Business Wire
Zura Bio to Participate in the Cantor Fitzgerald Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) ('Zura Bio' or the 'Company'), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today announced that its senior leadership team will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, September 4, 2025, at 2:45 PM ET in New York, NY. The Company will also conduct one-on-one investor meetings on the same day. A live webcast of the presentation will be available in the Investors section of the Company's website under News & Events. A replay will remain archived for at least 30 days. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The Company's pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit
Business Wire
32 minutes ago
- Business Wire
Bonerge Unveils StanYouth® CR3: A Revolutionary Anti-Aging Complex Merging TCM Wisdom and Cellular Science
NEW YORK--(BUSINESS WIRE)--Bonerge has unveiled its revolutionary anti-aging Product, StanYouth® CR3, a patented formula that bridges Traditional Chinese Medicine (TCM) philosophy with cutting-edge cellular science. Inspired by TCM's "Senolytic-Repair-Chi" theory, this synergistic complex targets aging at the cellular level, offering a multi-dimensional solution to combat senescence. Rooted in the TCM principle of "treating disease before it arises," StanYouth® CR3 operates through a three-stage mechanism mirroring "Senolytic-Repair-Chi." Its core ingredients—Fisetin (FIS), Urolithin A (UA), and L-Ergothioneine (EGT)—work in harmony to address aging at its source. Fisetin: The Senolytic Purifier As a natural flavonoid with superior cell membrane penetration, Fisetin selectively eliminates senescent cells—dysfunctional cells that linger and secrete pro-inflammatory senescence-associated secretory phenotypes (SASP), accelerating tissue aging. It not only clears existing senescent cells but also reduces new ones, cutting inflammatory factor production at the source to purify the cellular environment [1,2]. Urolithin A: The Homeostasis Restorer Cellular aging thrives on disrupted metabolic and circadian rhythms, which worsen inflammation and weaken clock gene function. Urolithin A repairs this balance by regulating core clock genes (e.g., CLOCK, PER2) critical for gut metabolism and boosting the expression amplitude of BMAL1 in senescent cells, restoring their circadian rhythms and metabolic homeostasis [3,4]. L-Ergothioneine: The Defense Enhancer Environmental stress and metabolism generate reactive oxygen/nitrogen species (ROS/RNS) that damage DNA and deplete vitality. L-Ergothioneine, via its unique OCTN-1 transporter, accumulates in high-oxidative-stress areas like mitochondria and nuclei, neutralizing free radicals in real time. It also upregulates endogenous antioxidant enzymes, strengthening cellular resilience and nourishing vital energy ("Chi")[5,6]. Synergistic Power: A Closed-Loop Mechanism Together, they form a "Senolytic-Repair-Chi" cycle. Fisetin clears senescent burdens, creating a healthy foundation; Urolithin A restores rhythms and metabolism; L-Ergothioneine fortifies defenses, preventing further damage—each amplifying the others' effects. Cellular Experiments Validate Superiority Tests on human dermal fibroblasts revealed striking results: StanYouth® CR3 cleared up to 80% of senescent cells, doubling Fisetin's solo performance. It suppressed senescence markers p16 and p21 to near-normal levels, outperforming single ingredients. Critically, it reduced pro-inflammatory IL-6, IL-8, and fibrosis-driving IL-11 to baseline, blocking the "senescence-inflammation-fibrosis" cycle. It also inhibited UVB-induced ROS and boosted cell migration —key for repair—far better than individual components. Clinical Trial Confirms Efficacy A 56-day human trial showed StanYouth® CR3 outperformed standalone L-Ergothioneine: skin firmness (F4) rose 16.3%, under-eye wrinkles fell 11.28%, brightness (L*) increased 1.4%, and fairness (ITA) improved 6.10%, skin barrier repair (TEWL reduction) reached 18.18%. "StanYouth® CR3 is more than an anti-aging formula— it's a bridge between ancient TCM wisdom and modern cellular science," noted a Bonerge product manager. By translating the holistic "Senolytic-Repair-Chi" principle into a precise, synergistic cellular strategy, it delivers proven efficacy from laboratory to real-world application. As Bonerge continues to explore its potential beyond skin health, StanYouth® CR3 marks a new era in evidence-based anti-aging, where tradition and innovation converge to redefine vitality. References [1] Kento Takaya, et al. Biogerontology. 2024 Feb;25(1):161-175. [2] Li Zhang, Xiang Tong, et al. Front Pharmacol. 2020 Dec 14:11:553690. [3] Yao Du, Xinyue Chen et al. Nutrients 2024, 16, 2263. [4] Rassul Kuatov, Jiro Takano et 2024 Dec 25;17(1):20. [5] Hui-Min Liu, Wei Tang, et al. Molecules. 2023 Feb 8;28(4):1648. [6] Yasaaswini Apparoo, Chia Wei Phan, et al. Exp Gerontol. 2022 Dec:170:111982.
CNBC
34 minutes ago
- CNBC
Walmart shrimp may have been exposed to radioactive material, FDA says
The Food and Drug Administration said Tuesday that the public should avoid eating certain frozen shrimp sold at Walmart due to concerns that the seafood may have been contaminated with radioactive material. Health officials said in a news release that it is investigating reports of Cesium-137 (Cs-137) contamination in shipping containers and frozen shrimp products processed by an Indonesian company, PT. Bahari Makmur Sejati of Indonesia, also known as BMS Food. Some of the raw frozen shrimp products processed by an Indonesian company are sold at Walmart stores in 13 states, including Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Missouri, Mississippi, Ohio, Oklahoma, Pennsylvania, Texas and West Virginia, according to the FDA. Among the products includes Walmart's "great value brand frozen shrimp," the health agency said. "If you have recently purchased raw frozen shrimp from Walmart that matches this description, throw it away," the FDA said. "Do not eat or serve this product." Health officials advised people to talk to their health care providers if they think they've been exposed to elevated levels of the contaminant. PT. Bahari Makmur Sejati and Walmart did not immediately return requests for comment. Cs-137 is the radioactive form of Cesium, "a soft, flexible, silvery-white metal that becomes liquid near room temperature" used for medical devices and gauges, according to the Environmental Protection Agency. Repeated exposure to low doses of Cs-137 can increase the risk of cancer, "resulting from damage to DNA within living cells of the body," health officials said in their news release. The FDA said that the U.S. Customs and Border Protection alerted the health agency to the detection of Cs-137 in shipping containers in Los Angeles, Houston, Miami and Savannah, Georgia. It said that all containers and products that tested positive for Cs-137 were denied entry into the country. Health officials also cautioned that it did not detect Cs-137 in any product above the current derived intervention levels for Cs-137, of 1200 Bq/kg. However, the FDA said that "the level detected in the breaded shrimp sample could represent a potential health concern" if it is combined with radiation in the environment or from medical procedures.
